Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Eiger Biopharmaceuticals (EIGRQ) just unveiled an update.
Eiger BioPharmaceuticals, Inc. has filed for Chapter 11 bankruptcy, reminding investors to exercise caution when dealing with its securities due to the unpredictable nature of its stock prices during the bankruptcy process. The company’s recent financial reports, required for court proceedings, are not in line with standard accounting practices and may not be a reliable indicator for investment decisions. Investors are warned that trading the company’s securities is highly speculative and may result in significant losses, depending on the outcome of the bankruptcy case. Forward-looking statements regarding the company’s intentions to continue operations during bankruptcy proceedings are uncertain and subject to various risks and assumptions.
For detailed information about EIGRQ stock, go to TipRanks’ Stock Analysis page.
